Keywords: Bristol-Myers Squibb, Hepatitis C, BMS-986094, Baxter Int, HyQ, Immunodeficiencies

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ

Article | 02 August 2012

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase II study of BMS-986094. The ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in